UnWNTing the Heart: Targeting WNT Signaling in Pulmonary Arterial Hypertension

HomeCirculation ResearchVol. 132, No. 11UnWNTing the Heart: Targeting WNT Signaling in Pulmonary Arterial Hypertension No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextUnWNTing the Heart: Targeting WNT Signaling in Pulmonary Arterial Hypertension Elena A. Goncharova, Tatiana V. Kudryashova, Vinicio A. de Jesus Perez and Olga Rafikova Elena A. GoncharovaElena A. Goncharova Correspondence to: Elena Goncharova, PhD, GBSF Rm 6523, 451 Health Sciences Dr, Davis, CA 95616. Email E-mail Address: [email protected] https://orcid.org/0000-0001-7118-6752 Lung Center, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis School of Medicine, Davis, CA (E.A.G., T.V.K.). Search for more papers by this author , Tatiana V. KudryashovaTatiana V. Kudryashova https://orcid.org/0000-0002-2843-5554 Lung Center, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis School of Medicine, Davis, CA (E.A.G., T.V.K.). Search for more papers by this author , Vinicio A. de Jesus PerezVinicio A. de Jesus Perez https://orcid.org/0000-0001-5532-8247 Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA (V.A.d.J.P.). Search for more papers by this author and Olga RafikovaOlga Rafikova Department of Medicine, Division of Endocrinology, University of Arizona College of Medicine, Tucson, AZ (O.R.). Search for more papers by this author Originally published25 May 2023https://doi.org/10.1161/CIRCRESAHA.123.322912Circulation Research. 2023;132:1486–1488This article is a commentary on the followingTargeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular RemodelingFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 1488.Correspondence to: Elena Goncharova, PhD, GBSF Rm 6523, 451 Health Sciences Dr, Davis, CA 95616. Email eagoncharova@ucdavis.eduReferences1. Hassoun PM. Pulmonary arterial hypertension.N Engl J Med. 2021; 385:2361–2376. doi: 10.1056/NEJMra2000348CrossrefMedlineGoogle Scholar2. Humbert M, Guignabert C, Bonnet S, Dorfmuller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.Eur Respir J. 2019; 53:1801887. doi: 10.1183/13993003.01887-2018CrossrefMedlineGoogle Scholar3. Aldred MA, Morrell NW, Guignabert C. New mutations and pathogenesis of pulmonary hypertension: progress and puzzles in disease pathogenesis.Circ Res. 2022; 130:1365–1381. doi: 10.1161/CIRCRESAHA.122.320084LinkGoogle Scholar4. Bernardo RJ, Haddad F, Couture EJ, Hansmann G, de Jesus Perez VA, Denault AY, de Man FS, Amsallem M. Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction.Cardiovasc Diagn Ther. 2020; 10:1580–1603. doi: 10.21037/cdt-20-479CrossrefMedlineGoogle Scholar5. Agrawal V, Lahm T, Hansmann G, Hemnes AR. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism.Cardiovasc Diagn Ther. 2020; 10:1522–1540. doi: 10.21037/cdt-20-404CrossrefMedlineGoogle Scholar6. Rafikov R, Coletta DK, Mandarino LJ, Rafikova O. Pulmonary arterial hypertension induces a distinct signature of circulating metabolites.J Clin Med. 2020; 9:217. doi: 10.3390/jcm9010217CrossrefMedlineGoogle Scholar7. Rim EY, Clevers H, Nusse R. The Wnt pathway: from signaling mechanisms to synthetic modulators.Annu Rev Biochem. 2022; 91:571–598. doi: 10.1146/annurev-biochem-040320-103615CrossrefMedlineGoogle Scholar8. Yousefi F, Shabaninejad Z, Vakili S, Derakhshan M, Movahedpour A, Dabiri H, Ghasemi Y, Mahjoubin-Tehran M, Nikoozadeh A, Savardashtaki A, et al. TGF-beta and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus.Cell Commun Signal. 2020; 18:87. doi: 10.1186/s12964-020-00555-4CrossrefMedlineGoogle Scholar9. Chakraborty A, Nathan A, Orcholski M, Agarwal S, Shamskhou EA, Auer N, Mitra A, Guardado ES, Swaminathan G, Condon DF, et al. WNT7A deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension [published online April 6, 2023].Eur Respir J. doi: 10.1183/13993003.01625-2022. https://erj.ersjournals.com/content/early/2023/03/01/13993003.01625-2022CrossrefGoogle Scholar10. de Jesus Perez V, Yuan K, Alastalo TP, Spiekerkoetter E, Rabinovitch M. Targeting the Wnt signaling pathways in pulmonary arterial hypertension.Drug Discov Today. 2014; 19:1270–1276. doi: 10.1016/j.drudis.2014.06.014CrossrefMedlineGoogle Scholar11. Andersen S, Nielsen-Kudsk JE, Vonk Noordegraaf A, de Man FS. Right ventricular fibrosis.Circulation. 2019; 139:269–285. doi: 10.1161/CIRCULATIONAHA.118.035326LinkGoogle Scholar12. Nayakanti SR, Friedrich A, Sarode P, Jafari L, Maroli G, Boehm M, Bourgeois A, Grobs Y, Khassafi F, Kuenne C, et al. Targeting Wnt-β-catenin-FOSL signaling ameliorates right ventricular remodeling.Circ Res. 2023; 132:1468–1485. doi: 10.1161/CIRCRESAHA.122.321725LinkGoogle Scholar13. Vallée A, Lecarpentier Y, Vallée JN. The key role of the WNT/β-catenin pathway in metabolic reprogramming in cancers under normoxic conditions.Cancers (Basel). 2021; 13:5557. doi: 10.3390/cancers13215557CrossrefMedlineGoogle Scholar14. Chen X, Yuan W, Li Y, Luo J, Hou N. Role of Hippo-YAP1/TAZ pathway and its crosstalk in cardiac biology.Int J Biol Sci. 2020; 16:2454–2463. doi: 10.7150/ijbs.47142CrossrefMedlineGoogle Scholar15. Shen Y, Goncharov DA, Pena A, Baust J, Chavez Barragan A, Ray A, Rode A, Bachman TN, Chang B, Jiang L, et al. Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension.Sci Signal. 2022; 15:eabn2743. doi: 10.1126/scisignal.abn2743CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesTargeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular RemodelingSreenath Reddy Nayakanti, et al. Circulation Research. 2023;132:1468-1485 May 26, 2023Vol 132, Issue 11 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.123.322912PMID: 37228239 Originally publishedMay 25, 2023 KeywordsEditorialchronic diseaseconstrictionprognosispulmonary arterial hypertensionPDF download Advertisement